Traitement par ganciclovir des infections congénitalesàcytomégalovirus

Es, Horning; Trindade, Eunice; Mateus, Maria do Nascimento Esteves; D'Orey, Conceição; ALMEIDA, ANA PATRÍCIA MARQUES DE; Martins, Aline Stangherlin; Souto, A.; Santos, Natacha

doi:10.1016/0929-693x(96)83238-6

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We further identified 13 case reports, comprising 16 children in all [1,3,11,13,14,18,26,29,30,32,[34][35][36], three case series [19,28,33] together including 20 patients, and present data from two larger studies, comparing different treatment regimens.…”

Section: Resultsmentioning

confidence: 99%

“…In the retained articles we found no babies with striatal vasculopathy who were treated with ganciclovir. Periventricular pseudocyst was reported in one article, but that baby also showed periventricular calcifications [13]. In the study of Williamson et al [38], asymptomatic babies with periventricular radiolucencies on computerized tomography (CT) scan suffered significantly more from SNHL (4/13) than asymptomatic babies with normal CT scan (2/40).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Selecting neonates with congenital cytomegalovirus infection for ganciclovir therapy

et al. 2006

View full text Add to dashboard Cite

All reported patients presented with central nervous system manifestation of CMV infection. Only the randomized controlled study showed a reduction of hearing deterioration in the treated group. Published predictors of hearing loss in congenitally CMV infected children allow identification of candidates that might benefit from treatment. Studies so far are promising but of insufficient number to make evidence based recommendations about indications for treatment of congenital CMV. As such, studies are very difficult to conduct and treatment of infants at high risk of hearing loss may appear justified. There is scientific data to help clinicians in selecting a subgroup of infants that is at higher risk of hearing deterioration and therefore might benefit the most from ganciclovir therapy.

show abstract